Triple-negative breast cancer (negative for ER, PR and HER2) accounts for about 10%–15% of breast cancers and is characterized by strong aggressiveness and high recurrence rate, and its lack of clear targeted therapeutic targets has led to poor prognosis and shorter overall survival in TNBC patients (Loibl et al., 2024). Here, ERBB2 is linked to breast cancer.